Terms: = Lung cancer AND ATRX, P46100, ZNF-HX, XNP, XH2, SHS, SFM1, RAD54, MRXHF1, MGC2094, ATR2, 546 AND Treatment
59 results:
1. Factors associated with prolonged progression-free survival of patients treated with first-line afatinib for advanced epidermal growth factor receptor-mutated non-small cell lung cancer.
Chiu LC; Hsu PC; Wang CC; Ko HW; Kuo SC; Ju JS; Tung PH; Huang AC; Yang CT
Thorac Cancer; 2024 Mar; 15(7):529-537. PubMed ID: 38279515
[TBL] [Abstract] [Full Text] [Related]
2. Immunomodulator use, risk factors and management of flares, and mortality for patients with pre-existing rheumatoid arthritis after immune checkpoint inhibitors for cancer.
McCarter KR; Arabelovic S; Wang X; Wolfgang T; Yoshida K; Qian G; Kowalski EN; Vanni KMM; LeBoeuf NR; Buchbinder EI; Gedmintas L; MacFarlane LA; Rao DA; Shadick NA; Gravallese EM; Sparks JA
Semin Arthritis Rheum; 2024 Feb; 64():152335. PubMed ID: 38100899
[TBL] [Abstract] [Full Text] [Related]
3. Outcome of immunotherapy in adrenocortical carcinoma: a retrospective cohort study.
Remde H; Schmidt-Pennington L; Reuter M; Landwehr LS; Jensen M; Lahner H; Kimpel O; Altieri B; Laubner K; Schreiner J; Bojunga J; Kircher S; Kunze CA; Pohrt A; Teleanu MV; Hübschmann D; Stenzinger A; Glimm H; Fröhling S; Fassnacht M; Mai K; Kroiss M
Eur J Endocrinol; 2023 Jun; 188(6):485-493. PubMed ID: 37260092
[TBL] [Abstract] [Full Text] [Related]
4. Uterine Leiomyosarcoma Masquerading as a Malignant Perivascular Epithelioid Cell Tumor: A Diagnostic Challenge.
Natsume T; Yoshida H; Nishikawa T; Kikkawa N; Naka T; Kobayashi-Kato M; Tanase Y; Uno M; Ishikawa M; Kato T
Int J Surg Pathol; 2023 Aug; 31(5):778-784. PubMed ID: 36310451
[TBL] [Abstract] [Full Text] [Related]
5. The cost-effectiveness of brigatinib in adult patients with ALK inhibitor-naive ALK-positive non-small cell lung cancer from a US perspective.
Cranmer H; Kearns I; Young M; Humphries MJ; Trueman D
J Manag Care Spec Pharm; 2022 Sep; 28(9):970-979. PubMed ID: 36001099
[No Abstract] [Full Text] [Related]
6. A retrospective cohort study predicting and validating impact of the COVID-19 pandemic in individuals with chronic kidney disease.
Dashtban A; Mizani MA; Denaxas S; Nitsch D; Quint J; Corbett R; Mamza JB; Morris T; Mamas M; Lawlor DA; Khunti K; ; Sudlow C; Hemingway H; Banerjee A
Kidney Int; 2022 Sep; 102(3):652-660. PubMed ID: 35724769
[TBL] [Abstract] [Full Text] [Related]
7. Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib.
Jin Y; Lin C; Shi X; He Q; Yan J; Yu X; Chen M
BMC Cancer; 2022 May; 22(1):586. PubMed ID: 35643428
[TBL] [Abstract] [Full Text] [Related]
8. Current situation of fungal diseases in Eritrea.
Werkneh S; Orefuwa E; Denning DW
Mycoses; 2022 Aug; 65(8):806-814. PubMed ID: 35633079
[TBL] [Abstract] [Full Text] [Related]
9. [Impact of neoadjuvant immunotherapy on pulmonary function and perioperative outcomes in patients with resectable non-small cell lung cancer].
Zhu Y; Li JQ; Chang Q; Qiang HP; Lu JH; Feng H; Shen YC; Qian JL; Chu TQ
Zhonghua Yi Xue Za Zhi; 2022 Feb; 102(6):393-398. PubMed ID: 35144337
[No Abstract] [Full Text] [Related]
10. Use of Theory-Driven Report Back to Promote lung cancer Risk Reduction.
Huntington-Moskos L; Rayens MK; Wiggins AT; Butler KM; Hahn EJ
Int J Environ Res Public Health; 2021 Oct; 18(20):. PubMed ID: 34682394
[TBL] [Abstract] [Full Text] [Related]
11. The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms.
Venizelos A; Elvebakken H; Perren A; Nikolaienko O; Deng W; Lothe IMB; Couvelard A; Hjortland GO; Sundlöv A; Svensson J; Garresori H; Kersten C; Hofsli E; Detlefsen S; Krogh M; Sorbye H; Knappskog S
Endocr Relat Cancer; 2021 Nov; 29(1):1-14. PubMed ID: 34647903
[TBL] [Abstract] [Full Text] [Related]
12. Is it Unjustified to Perform Segmentectomy in Surgical treatment of lung Adenocarcinoma?
Sezer HF; Eliçora A; Topçu S
Arch Iran Med; 2021 Jun; 24(6):487-495. PubMed ID: 34488312
[TBL] [Abstract] [Full Text] [Related]
13. Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor treatment for cancer.
Cunningham-Bussel A; Wang J; Prisco LC; Martin LW; Vanni KMM; Zaccardelli A; Nasrallah M; Gedmintas L; MacFarlane LA; Shadick NA; Awad MM; Rahma O; LeBoeuf NR; Gravallese EM; Sparks JA
Arthritis Rheumatol; 2022 Mar; 74(3):527-540. PubMed ID: 34397169
[TBL] [Abstract] [Full Text] [Related]
14. Cost-Effectiveness Analysis of Cemiplimab Versus Chemotherapy as First-Line treatment in Advanced NSCLC with PD-L1 Expression Levels of at Least 50.
Wang L; Peng Y; Zeng X; Peng L; Li S; Qin S; Wan X; Tan C
Adv Ther; 2021 Aug; 38(8):4354-4365. PubMed ID: 34241780
[TBL] [Abstract] [Full Text] [Related]
15. AT-RvD1 Mitigates Secondhand Smoke-Exacerbated Pulmonary Inflammation and Restores Secondhand Smoke-Suppressed Antibacterial Immunity.
Bhat TA; Kalathil SG; Bogner PN; Lehmann PV; Thatcher TH; Sime PJ; Thanavala Y
J Immunol; 2021 Mar; 206(6):1348-1360. PubMed ID: 33558371
[TBL] [Abstract] [Full Text] [Related]
16. Having a co-morbidity predicts worse outcome in early rheumatoid arthritis despite intensive treatment: a post hoc evaluation of the pragmatic randomized controlled CareRA trial.
Stouten V; Westhovens R; De Cock D; Van der Elst K; Pazmino S; Bertrand D; Joly J; Verschueren P
Rheumatology (Oxford); 2021 Aug; 60(8):3699-3708. PubMed ID: 33434277
[TBL] [Abstract] [Full Text] [Related]
17. Blood prognostic predictors of treatment response for patients with papillary thyroid cancer.
Liu X; Huang Z; He X; Zheng X; Jia Q; Tan J; Fan Y; Lou C; Meng Z
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33015713
[TBL] [Abstract] [Full Text] [Related]
18. Neurologic autoimmunity and immune checkpoint inhibitors: Autoantibody profiles and outcomes.
Sechi E; Markovic SN; McKeon A; Dubey D; Liewluck T; Lennon VA; Lopez-Chiriboga AS; Klein CJ; Mauermann M; Pittock SJ; Flanagan EP; Zekeridou A
Neurology; 2020 Oct; 95(17):e2442-e2452. PubMed ID: 32796130
[TBL] [Abstract] [Full Text] [Related]
19. Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer.
Li M; Spakowicz D; Zhao S; Patel SH; Johns A; Grogan M; Miah A; Husain M; He K; Bertino EM; Shields PG; Wei L; Carbone DP; Otterson GA; Presley CJ; Owen DH
Cancer Immunol Immunother; 2020 Nov; 69(11):2403-2408. PubMed ID: 32728772
[TBL] [Abstract] [Full Text] [Related]
20. Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol.
Bongiovanni A; Liverani C; Pusceddu S; Leo S; Di Meglio G; Tamberi S; Santini D; Gelsomino F; Pucci F; Berardi R; Lolli I; Bergamo F; Ricci S; Foca F; Severi S; Ibrahim T;
BMJ Open; 2020 Jul; 10(7):e034393. PubMed ID: 32690499
[TBL] [Abstract] [Full Text] [Related]
[Next]
